We are live on ! Find out more
OTLKW

Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW

Delisted

OTLKW was delisted on the 16th of February, 2022.

Back to rankings

4 hedge funds and large institutions have $663K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

354% more capital invested

Capital invested by funds: $146K → $663K (+$517K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
$282K
Puts
–
Net Calls
+$282K
Net Calls Change
+$119K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$322K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$93K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$421K +$322K +416,666 New
SFM
2
Sphera Funds Management
Israel
$131K – – –
PC
3
PointState Capital
New York
$101K – – –
CIA
4
Compass Ion Advisors
Pennsylvania
$10K – – –
PA
5
Perceptive Advisors
New York
– -$93K -420,875 Closed

OTLKW Hedge Fund Activity: Q1 2021 in Review

4 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q1 2021, worth a combined $663K — up 354% from $146K a quarter earlier.

Fund positioning in OTLKW was balanced in Q1 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $322K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $93K sold.

  • 4 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $663K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q1 2021, up 354% quarter-over-quarter.
  • 1 fund opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q1 2021 and 1 closed out, a net change of 0 holders.
  • The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q1 2021 was Cormorant Asset Management, an estimated $322K added.
  • The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q1 2021 was Perceptive Advisors, an estimated $93K sold.

Based on aggregated 13F filings for Q1 2021.